We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

288 hedge funds and large institutions have $5.34B invested in Intra-Cellular Therapies Inc. in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 115 increasing their positions, 78 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more call options, than puts

Call options by funds: $16.6M | Put options by funds: $10.7M

47% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 78

42% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 36

38% more funds holding in top 10

Funds holding in top 10: 8 → 11 (+3)

18% more capital invested

Capital invested by funds: $4.55B → $5.34B (+$797M)

5% more funds holding

Funds holding: 274 → 288 (+14)

Holders
288
Holders Change
+14
Holders Change %
+5.11%
% of All Funds
4.52%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.17%
New
51
Increased
115
Reduced
78
Closed
36
Calls
$16.6M
Puts
$10.7M
Net Calls
+$5.94M
Net Calls Change
-$34M

Top Buyers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$36.7M
2
Holocene Advisors
Holocene Advisors
New York
+$36.1M
3
Macquarie Group
Macquarie Group
Australia
+$35.4M
4
NIP
Nicholas Investment Partners
California
+$31.1M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$30.5M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$207M
2
WA
Wasatch Advisors
Utah
-$62M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$47.1M
4
DM
Deerfield Management
New York
-$39.7M
5
Citadel Advisors
Citadel Advisors
Florida
-$36.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
CP
301
CenterBook Partners
Connecticut
– -$868K -16,029 Closed
PAM
302
Panagora Asset Management
Massachusetts
– -$846K -15,627 Closed
HSA
303
Hussman Strategic Advisors
Maryland
– -$839K -15,500 Closed
MC
304
Maverick Capital
Texas
– -$490K -9,057 Closed
E
305
Ergoteles
New York
– -$479K -8,842 Closed
Wolverine Trading
306
Wolverine Trading
Illinois
– -$482K -8,602 Closed
XT
307
XTX Topco
Cayman Islands
– -$411K -7,583 Closed
CCIA
308
Campbell & Co Investment Adviser
Maryland
– -$377K -6,962 Closed
PCM
309
Penserra Capital Management
California
– -$372K -6,876 Closed
Canada Pension Plan Investment Board
310
Canada Pension Plan Investment Board
Ontario, Canada
– -$363K -6,700 Closed
MFS
311
Mirabella Financial Services
United Kingdom
– -$4.02M -6,267 Closed
Rockefeller Capital Management
312
Rockefeller Capital Management
New York
– -$275K -5,085 Closed
WG
313
Winton Group
United Kingdom
– -$245K -4,527 Closed
TI
314
Tidal Investments
Wisconsin
– -$216K -3,980 Closed
NRD
315
Nebula Research & Development
New York
– -$214K -3,960 Closed
CC
316
Centiva Capital
New York
– -$202K -3,735 Closed
BAM
317
Belpointe Asset Management
Nevada
– -$68K -1,256 Closed
ASN
318
Advisory Services Network
Georgia
– -$30.8K -568 Closed
TWA
319
TCI Wealth Advisors
Arizona
– -$11K -204 Closed
IUHSA
320
Itau Unibanco Holding S.A.
Brazil
– -$8.18K -151 Closed
MIA
321
Milestone Investment Advisors
Wisconsin
– -$2.17K -40 Closed
MFG
322
Mendota Financial Group
Wisconsin
– -$1.22K -20 Closed
Northwestern Mutual Wealth Management
323
Northwestern Mutual Wealth Management
Wisconsin
– -$162 -3 Closed
9 10 11 12
13

ITCI Hedge Fund Activity: Q2 2023 in Review

288 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2023, worth a combined $5.34B — up 18% from $4.55B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new ITCI positions and 36 closed out — a net gain of 15 holders — while 115 added to existing stakes and 78 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $36.7M. The largest seller was Wellington Management Group, cutting an estimated $207M.

  • 288 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2023, up from 274 in Q1 2023.
  • Funds reported $5.34B of Intra-Cellular Therapies Inc. stock for Q2 2023, up 18% quarter-over-quarter.
  • 51 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2023 and 36 closed out, a net change of +15 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2023 was Lord, Abbett & Co, an estimated $36.7M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2023 was Wellington Management Group, an estimated $207M sold.

Based on aggregated 13F filings for Q2 2023.